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ABSTRACT 
Purpose: Medication-related clinical decision support (CDS) has been identified as a method to 
improve patient outcomes but are historically frequently overridden and may be inappropriately 
so. Patients in the intensive care unit (ICU) are at a higher risk of harm from adverse drug events 
(ADEs) and these overrides may increase patient harm. The objective of this study is to 
determine appropriateness of overridden medication-related CDS overrides in the ICU. 
Materials and Methods: We evaluated overridden medication-related alerts of four alert 
categories from January 2009 to December 2011. The primary outcome was the appropriateness 
of a random sample of overrides based on predetermined criteria. Secondary outcomes included 
the incidence of adverse drug events (ADEs) that resulted from the overridden alert. 
Results: A total of 47,449 overridden alerts were included for evaluation. The appropriateness 
rate for overridden alerts varied by alert category (allergy: 94%, drug-drug interaction: 84%, 
geriatric: 57%, renal 27%). A total of seven actual ADEs were identified in the random sample 
and where the medication(s) was administered (n = 366), with an increased risk of ADEs 
associated with inappropriately overridden alerts (p = 0.0078).   
Conclusions: The appropriateness of medication-related clinical decision support overrides in 
the ICU varied substantially by the type of alert. Inappropriately overridden alerts were 
associated with an increased risk of ADEs compared to appropriately overridden alerts.  
 
Keywords: Adverse drug event; clinical decision support; critical care; patient safety; quality of 
care   
4 
 
INTRODUCTION 
Clinical decision support (CDS) aims to improve health care by enhancing decision-
making in both inpatient and outpatient settings. Medication-related CDS can assist users when 
ordering medications and provide potential warnings regarding ordered therapy. Despite 
evidence to support the benefits of CDS in reducing adverse drug events (ADEs), costs, hospital 
length of stay and patient morbidity and mortality, there is also a growing body of evidence 
detailing how these alerts or warnings are regularly overridden. [1-4] The incidence of alert 
overriding is high in the outpatient setting, as demonstrated by an override rate of 52.6 per 100 
alerts. [3,4] Only 53% of these overrides were identified as appropriate, defined as a false 
positive alert (i.e., an alert that was not clinically relevant to the patient). In a Veterans Affairs 
population, one study found that the override rate of critical alerts was 87%. [5] Explanations for 
overrides include poorly constructed alerts and alert fatigue. [4] However, CDS overrides may 
lead to a spectrum of patient harm from no harm to irreversible harm. ADEs have been 
associated with additional healthcare costs, increased hospital length of stay, and increased 
mortality. [6-9] However, literature associating CDS overrides with increased patient harm is 
limited. [10-11] 
Patients in the intensive care unit (ICU) are particularly susceptible to ADEs. These 
patients may be at greater risk than general ward patients for a variety of reasons, including 
altered pharmacokinetics, an increased length of stay and an increased number of medications 
administered. [12-16] Continuation of a patient’s home medications may also be a potential 
cause of ADEs, given a patients altered pharmacokinetics. Prospective cohort studies identifying 
ADEs in the ICU found them to be common, with rates varying from 30.6 to 96.5 per 1,000 
patient days, associated with morbidity but not associated with increased mortality. [17,18] 
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Given the benefits of CDS, overrides of available alerts may lead to increased risk of patient 
harm in the ICU.  
However, few studies exist evaluating the appropriateness of CDS alert overrides in 
inpatients and we could not identify previous studies evaluating overrides in intensive care. 
Therefore, we performed a study to characterize the appropriateness of CDS overrides in the 
ICU, including their potential association with harm.  
MATERIALS AND METHODS 
 
This study was a retrospective, observational study evaluating medication-related CDS 
alert overrides by providers. Alert overrides were generated between January 2009 and 
December 2011 from patients admitted to an adult ICU at Brigham and Women’s Hospital. The 
alerts targeted were focused on alert types that have a high occurrence and significance in the 
ICU patient population: drug-allergy, drug-drug interaction (DDI), geriatric (age ≥ 65 years) and 
renal (creatinine clearance calculated by the Cockcroft-Gault equation). [19] The proprietary 
Partners Healthcare System Knowledge Base was used as the basis of the DDI, geriatric and 
renal alerts, which had been customized over years based on end-user feedback and prospective 
review of literature. [20,21] Allergy alert logic was sourced from First DataBank (First 
DataBank, South San Francisco, CA, USA). 
A few alerts occurred very frequently and overrides were generally considered 
appropriate, and these were excluded and therefore considered the “unevaluated” alerts.  These 
were as follows:  
 DDI – epidural bupivicaine and anticoagulants ordered appropriately per 
institution policy, limited systemic absorption, intravenous calcium and 
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ceftriaxone alerts which were intended to fire only in neonatal patients, and alerts 
involving absorption issues, but with a medication ordered in a parenteral form;  
 Geriatric – short-term laxative use;  
 Renal – aspirin dosed for cardioprotection (defined as ≤325 mg daily). [22]  
The primary outcome was the appropriateness of the remaining overrides, assessed by 
two independent reviewers with a set of predetermined criteria specific for each type of alert. 
Secondary outcomes included the documented reason for override and the incidence of ADEs 
associated with overrides. Outcome evaluation was only completed on the “evaluated alerts” (i.e. 
alerts that were not excluded as they could be appropriate or inappropriate). This study was 
approved by the Partners Institutional Review Board. 
Appropriateness Evaluation  
Criteria for appropriateness were created via previously published data, including 
guidelines, as well as clinical experience of a multidisciplinary group. [23] Criteria were specific 
for alert categories and modified until a consensus was reached for all criteria. A random sample 
of 100 evaluated alerts (termed “random sample”) in each of the alert categories was selected for 
determination of appropriateness. Two clinical pharmacists independently evaluated the 
appropriateness of overrides. The inter-rater agreement for appropriateness was determined via a 
κ statistic. Disagreements were resolved via discussion between the two independent reviewers. 
If consensus was not achieved, a third experienced reviewer was consulted. The κ for the criteria 
agreement of appropriateness was 0.79 (95% CI 0.73-0.86) indicating substantial agreement, 
with a percent agreement of 90.6%.  
Override Rationale Evaluation 
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A rationale for overriding the alert was required to be provided only for allergy and DDI 
alerts; override reasons for geriatric and renal medication alerts were optional. Rationale was 
grouped based on choice from a drop-down menu (i.e. coded reasons), while related free-text 
entries were grouped together based on patterns. These system-coded reasons were available in 
the data for evaluation. The override reason, if provided, was also utilized in the appropriateness 
evaluation (e.g. if a prescriber gave the reason ‘will monitor as recommended,’ then the medical 
record was evaluated for related monitoring). 
ADE Evaluation 
To evaluate for ADEs, we performed patient chart reviews on the random sample of 
overrides (n = 400). In 366 cases, the patient actually received the medication. ADEs were 
specific to the overridden alert (e.g. amiodarone and levofloxacin DDI, only evaluating QTc and 
documentation of dysrrhythmia). Data relevant to an ADE, such as patient comorbidities, 
laboratory reports, medication orders and patient notes documented by nurses or providers, were 
abstracted and summarized by one reviewer. These data were blinded (i.e. appropriateness of 
override was not provided) and forwarded to two independent reviewers to determine if an ADE 
occurred (no ADE, probable ADE, definite ADE), the severity of the ADE (significant, serious, 
life-threatening, fatal) and whether it was considered preventable (non-preventable, preventable). 
If consensus was not achieved, a third experienced reviewer was consulted. ADEs of 
inappropriately overridden alerts were defined as preventable, as there was a CDS alert that 
could have prevented the medication from being ordered. Study personnel had undergone 
training based on curriculum developed by the Center for Excellence for Patient Safety Research 
at Brigham and Women’s Hospital. This training has been used in previous studies and has been 
previously described. [24]  
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Statistical Analysis 
Descriptive statistics were used to summarize patient and alert characteristics. A chi-
square or Fisher’s exact test was used to compare categorical variables. An exact binomial 
calculation was used to determine confidence intervals within the observed samples.  
Approximate binomial confidence intervals were calculated for the weighted population average 
ADE rates in appropriately and inappropriately overridden alerts.  Because observed ADE rates 
of 0 in some categories would underestimate the variances, the population weighted rate was 
used instead. Both an exact Fisher test and an exact Poisson regression, adjusted for alert 
categories, were used to compare the rates of ADEs between the appropriately and 
inappropriately overridden alerts in the random sample. A p-value of < 0.05 was considered 
significant. Statistical analysis was completed using SAS 9.3 (SAS Institute Inc., Cary, NC, 
USA). 
RESULTS 
 
A total of 59,175 overridden medication-related alerts were fired for patients who were 
admitted to the ICU between January 2009 and December 2011. A total of 47,449 alerts (80.2%) 
were considered in our evaluated sample for appropriateness (Figure 1), and, unless otherwise 
noted, constitute the analysis sample. Allergy alerts accounted for the majority of CDS overrides 
(84.4%). 
There were a total of 4,776 unique patient encounters overall in the study population 
(Table 1). Patients with overridden geriatric and renal alerts tended to be older than in the other 
groups, as expected. Patients were primarily located in the cardiac surgery or medical ICUs at 
the time of alert override. 
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The three most common triggering medication(s) alerted in each of the different types of 
alerts and the route of administration are described in Table 2. There were a total of 4,502 unique 
overridden patient-allergy alerts (i.e. one unique allergy record per patient) (11.2%). The three 
most common reactions to the allergen were ‘unknown’ (n = 1,264, 28.1%), ‘rash’ (n = 562, 
12.5%) and ‘GI upset’ (n = 398, 8.8%). The three most common reasons given for overriding 
allergy alerts were ‘patient has taken previously without allergic reaction/patient has tolerated 
previously’ (n = 20,514, 51.2%), ‘physician aware’ (n = 7,729, 19.3%) and ‘low risk cross 
sensitivity will monitor’ (n = 5,128, 12.8%). A total of 194 unique DDI alerts (i.e., unique 
medication combinations) were overridden in our evaluation. Regarding categories of DDI alerts 
overridden using the whole sample, alerts indicating an increased risk of QTc prolongation (n = 
1,194, 30.8%) was most common, with alerts regarding myopathy (n = 885, 22.8%) and risk of 
altered medication levels, such as digoxin (n = 666, 17.2%), also being relatively common. The 
three most common override reasons were ‘will monitor as recommended’ (n = 1,911, 49.3%), 
‘will adjust dose as recommended’ (n = 522, 13.5%) and ‘patient has already tolerated 
combination’ (n = 418, 10.8%). A total of 58 unique medications were overridden in the geriatric 
alerts, while only nine unique medications were overridden in the renal alert category.  
Table 3 details findings on the appropriateness of overrides, as well as the number of 
overrides that were related to documented home medication and their associated appropriateness. 
The incidence of appropriateness varied significantly by alert category (p<0.001). The weighted 
appropriateness for all alerts (unevaluated and evaluated alerts) was 92.3%. Of the 138 
inappropriately overridden alerts, 117 (84.8%) of the associated medication(s) were administered 
to the patient. The renal alerts were most frequently linked to an inappropriate override where the 
associated medication was not administered to the patient (n = 18, 85.7%). The most common 
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medications associated with an inappropriate override for the allergy, DDI, geriatric, and renal 
alert categories were cefazolin (n = 2, 33.3%), simvastatin (n = 7, 43.8%), clonazepam (n = 11, 
25.6%), and hydrochlorothiazide (n = 32, 43.8%). Table 4 details the number of overrides per 
patient encounter and the number of  unique overrides per patient encounter. 
A total of 366 overrides (91.5%) from the random sample were evaluated for ADEs in the 
medical record as they resulted in medication(s) administration to the patient. A total of seven 
ADEs were identified (1.9% of random sample alert overrides) and most were from 
inappropriately overridden alerts (n = 6, 85.7%). The rate of ADEs per 100 overridden alerts for 
the appropriately and inappropriately overridden alerts were 0.091 (95% CI 0.036-0.146) and 
11.06 (95% CI 5.62-16.50), respectively. The proportion of ADEs per alert category and 
appropriateness of override are provided in Table 5, including 95% confidence intervals. Details 
of the ADEs identified are located in Table 6, such as the type of alert, alert and clinical scenario 
details, where the ADE occurred (i.e., in the ICU or on the general ward/floor) and the ADE 
classification. Inappropriately overridden alerts had a significantly higher incidence of ADEs (6 
ADEs in 138 overridden alerts) than appropriately overridden alerts (1 in 262) overall 
(p=0.0078), although the difference did not reach significance in any specific category because 
of the small sample sizes. A Poisson comparison using ADE rates, adjusted for the individual 
alert categories, also found similar results (p = 0.011). 
DISCUSSION 
 
We evaluated the appropriateness of medication-related CDS overrides in the ICU and 
potential harm associated with such actions. The appropriateness varied significantly by the type 
of alert and location where allergy overrides were commonly appropriately overridden. Renal 
alerts were commonly inappropriately overridden. Inappropriate overrides were associated with 
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an increased risk of ADEs. Appropriateness rates differed slightly from the published literature; 
however, this is likely due to the alert types studied and the close monitoring in the ICU, which 
affected our appropriateness criteria. [4,5,20] 
The CDS at our institution has been continuously modified over the years, with 
previously documented success. [20,21] This CDS has been tailored to decrease the number of 
non-pertinent alerts; however, we believe it should be possible to decrease the override rate 
further by turning off more of the relatively unimportant warnings. [25,26] In the future, alerts 
regarding recommended medications and doses should take into account patient context and 
include multiple patient-specific factors of concern. [26] We believe that allowing providers to 
control which alerts they can see would lead to problems, as studies demonstrate a significant 
positive correlation between the number of overridden alerts and the number of providers 
recommending alerts to be turned off. [27] 
The finding that almost all allergy overrides were appropriately overridden indicates that 
this is an area that needs improvement with respect to specificity, especially given the large 
amount of CDS overrides that allergy alerts accounted for. This is compounded by the finding 
that the majority of allergy overrides were for the documented reason that the patient had 
previously tolerated the medication; therefore, perhaps such alerts should be turned off if this is 
known to be the case. Eliminating the duplicative nature of these alerts should be a focus in 
improving the effectiveness of this type of CDS alert. If a provider has to override the same 
allergy alert for a specific patient nine times, this represents a problem which is wasting provider 
time and contributing to alert fatigue. In an evaluation of the allergy database at our institutions, 
44.5% of allergy reactions were non-immune-mediated. [28] Given the high incidence of 
overrides at our institution involving opioid ‘allergies’ documented with a reaction of 
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gastrointestinal intolerance, this is clearly an area with opportunity for improvement. [29,30] 
Additionally, exact versus non-exact matches of documented allergy and ordered medication and 
associated cross-sensitivity may also need to be considered. The allergy CDS alerts for all 
patients who had their home medication continued were determined to have been appropriately 
overridden. These alerts could probably be safely suppressed or a reminder for the provider to 
remove the documented allergy, if appropriate. 
Characteristics of the overridden DDI and geriatric alerts do not seem especially 
surprising. Given the constant monitoring of ICU patients, overrides were largely appropriate. 
However, this degree of monitoring may give a false sense of security given the severity of some 
interactions. [27] The types of medications involved for both alerts were expected, as the alerts 
were triggered by the medications most commonly used. A potential explanation for the 
disproportionate number of males in the DDI population is regarding the common medications 
and the increased risk of atrial fibrillation and coronary heart disease in males. [31,32] Regarding 
two of the most common types of DDIs, one study indicated that interactions involving 
medications that are QTc-prolonging or increase the risk of myopathy were unanimously voted 
by providers not to be turned off. [27] Additionally, one pre-post intervention study involving 
CDS in the ICU and QTc-prolonging DDIs found a decrease in related ADEs by 64%. [33] 
The low appropriateness rate of overridden renal alerts was a finding consistent with 
other published literature. [4] One proposed explanation is the ICU population is at high risk of 
acute kidney injury (AKI). This develops in approximately one-quarter of hospitalized patients; 
however, it is even more common in the ICU, with rates up to 60%. [34] Home medications were 
continued in one-third of patients, triggering a renal alert which was overridden. This override 
frequency was surprising. Home medications should be carefully scrutinized in the ICU because 
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of the potential for profound metabolic disturbances. Given the various alternative options 
available for many medications (i.e., furosemide for hydrochlorothiazide, insulin for glyburide), 
this was a surprising finding that safer and/or more effective alternative options were not used.  
The rate of ADEs associated with overrides may appear low relative to other published 
data including total ADE rates. [16-18] However, this was related to the study design, which 
limited ADE review to the override alerts for which the related medication was administered to 
the patient. Based on our appropriateness evaluation, inappropriate overrides accounted for 
approximately 10% of overrides in the ICU. The heavy weighting provided by the allergy 
overrides due to their high number and high prevalence of appropriateness heeds caution in 
interpretation as the appropriateness rate varied significantly by alert category. Inappropriate 
overrides likely account for a large portion of ordered medications, especially those related to 
renal alerts, in the ICU. Additionally, interpretation of the 95% confidence intervals may be 
affected by the low rate of ADEs in our study. 
Some methods that may serve to improve available CDS are as follows: for allergies, 
differentiation of alerts based on true allergy versus medication intolerance and how the 
information is presented [30]; for DDIs, incorporation of monitoring (e.g., levels) into the CDS 
alert when the documented reason for override involves ‘will monitor’ [35]; for renal alerts, 
incorporation of a method to determine if the patient has AKI (e.g. trend in serum creatinine, if 
recent data is available). Early detection of AKI would be of most benefit, although data 
supporting CDS remains controversial. [36] Finally, it may be useful to inform providers that 
overrides and their documented reason for override are being evaluated. [37] 
Our study had several limitations. First, this study was completed at a single-center. As 
our institution has continually aimed to improve our internally-developed medication-related 
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CDS, it had already been tailored and differed from that in the broader marketplace. Application 
to commercial databases may be limited, as the number of alerts in our database is likely smaller 
than other available databases. Second, this was a retrospective evaluation, which limited the 
determination of appropriateness and ADEs to the extent of documentation. Therefore, this is 
likely an underestimate of the actual amount of ADEs associated with these overrides. However, 
this study details the methods and provides a baseline estimate of override rates in the ICU. 
Additionally, our random sample was biased towards those patients who had multiple overrides, 
as they would have a higher chance to be included. Potentially, the higher number of overrides 
may be because those alerts were not clinically relevant and therefore, appropriately overridden. 
Finally, the appropriateness rate is also only applicable to overrides and not at a patient level, as 
this was not evaluated in our study. Future work in additional centers is warranted to validate 
rates in ICUs with commercial CDS databases. Although inappropriately overridden alerts were 
associated with an increased risk of ADEs, our study design prevents evaluation of causality. 
Third, alert fatigue may have resulted in providers selecting override reasons on allergy and DDI 
alerts that were not truly reflective of the rationale motivating their actions. Findings from 
evaluation of overrides in the primary care setting indicated that only approximately 35% of DDI 
alert overrides with an override reason of ‘will monitor as recommended’ actually had 
monitoring performed. [38] 
CONCLUSIONS 
 
We evaluated the appropriateness of medication-related CDS overrides in the ICU, and 
found that approximately 92% were appropriate, based on the weighted numbers. Given the high 
complexity of ICU patients, it is important to learn how CDS affects outcomes in this population. 
We identified a number of alerts that could likely be safely suppressed. Future studies should 
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validate rates in additional centers, define the “optimal” override rate in this population, examine 
how CDS can be made more patient-specific, and how CDS alerts affect patient outcomes in the 
ICU. 
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Tables 
 
Table 1. Demographics of Unique Patients Encounters 
 Allergy  
(n = 2934) 
DDI  
(n = 1230) 
Geriatric  
(n = 1332) 
Renal  
(n = 65) 
Total  
(n = 4776) 
Age, y, 
mean±SD 
63.3±15.6 64.0±15.0 71.7±7.4 
73.0 
(63.5,83.0)* 
65.4±14.8 
Male, n (%) 1209 (41.2) 730 (59.3) 689 (51.7) 27 (44.3) 2320 (48.6) 
Type of ICU, n (%) 
   Burn 192 (6.5) 99 (8.0) 92 (6.9) 8 (12.4) 274 (5.7) 
   Cardiac    
   Surgery 
1061 (36.2) 383 (31.1) 474 (35.6) 22 (33.8) 1668 (34.9) 
   Coronary 286 (9.7) 198 (16.1) 128 (9.6) 11 (16.9) 554 (11.6) 
   Medical 963 (32.8) 381 (31.0) 388 (29.1) 14 (21.5) 1544 (32.3) 
   Neurology 113 (3.9) 41 (3.4) 73 (5.5) 2 (3.1) 212 (4.4) 
   Surgical 126 (4.3) 28 (2.3) 78 (5.9) 5 (7.7) 149 (3.1) 
   Thoracic 193 (6.6) 100 (8.1) 99 (7.4) 3 (4.6) 375 (8.0) 
* Median (IQR) 
DDI = drug-drug interaction, ICU = intensive care unit 
 
 
Table 2. Characteristics of Overridden Alerts by Category with Top 3 Triggering Medications 
 
Allergy  
(n = 40056) 
DDI  
(n = 3877) 
Geriatric  
(n = 3414) 
Renal  
(n = 102) 
Enteral 
route, n (%) 
18515 (46.3) 4365 (56.3)* 2973 (87.1) 76 (74.5) 
Top 3 triggering medication(s), (n, %) 
     1. 
Penicillins 
(7330, 18.3) 
Amiodarone, 
levofloxacin 
(303, 7.8) 
Oxycodone and 
acetaminophen 
(663, 19.4) 
Hydrochlorothiazide 
(43, 42.2) 
     2. 
Codeine 
(4526, 11.3) 
Amiodarone, 
digoxin (291, 7.5) 
Clonazepam 
(517, 15.1) 
Ketorolac 
(20, 19.6) 
     3. 
Morphine 
(2964, 7.4) 
Diltiazem, 
simvastatin 
(256, 6.6) 
Alprazolam 
(437, 12.8) 
Ibuprofen 
(10, 9.8) 
* Accounts for both medications in interaction 
DDI = drug-drug interaction 
  
 Table 3. Appropriateness of Overridden Alerts 
 Allergy  
(n = 100) 
DDI  
(n = 100) 
Geriatric  
(n = 100) 
Renal  
(n = 100) 
Appropriate, n (%) 94 (94.0) 84 (84.0) 57 (57.0) 27 (27.0) 
Home medication, n (%) 10 (10.0) 36 (36.0) 40 (40.0) 46 (46.0) 
Appropriate home medication, n 
(% of total home medication) 
10 (100.0) 28 (77.8) 29 (72.5) 11 (23.9) 
DDI = drug-drug interaction 
 
 
Table 4. Numbers of Overridden Alerts per Patient Encounter 
 Allergy  DDI Geriatric Renal  
Overrides per patient encounter, 
median n (IQR) (Range) 
6 (2, 12) 
(1-660) 
1 (1, 2) 
(1-32) 
2 (1, 3) 
(1-25) 
1 (1,2) 
(1-5) 
Unique overrides per patient 
encounter, median n (IQR) 
(Range) 
4 (2, 9) 
(1-325) 
2 (1, 4) 
(1-32) 
2 (1, 3) 
(1-25) 
1 (1,2) 
(1-4) 
DDI = drug-drug interaction; IQR = interquartile range 
 
 
Table 5. Adverse Drug Events per Alert Category and Appropriateness 
 Allergy  DDI  Geriatric  Renal  
Appropriate, % 
(95% CI) 
0  
(0, 4.1) 
1.4  
(0.36, 17.0) 
0  
(0, 6.3) 
0  
(0, 14.2) 
Inappropriate, % 
(95% CI) 
16.7  
(0.4, 64.1) 
0 
(0, 21.8) 
7.1 
(1.4, 18.3) 
3.6 
(0.4, 11.9) 
DDI = drug-drug interaction 
  
Table 6. Adverse Drug Events Occurring after Alert Override 
Type of Alert Alert and Clinical Scenario Details Classification 
Drug-drug 
interaction 
 Amiodarone – levofloxacin 
 QTc prolongation 
 Override reason: “Will monitor as 
recommended” 
 Increase in QTc from 448 to 581, 
with daily monitoring 
 Appropriate override 
 Probable ADE 
 Occurrence of ADE: ICU 
 Severity: serious 
 Non-preventable 
Allergy  Vancomycin – Red man syndrome 
 Ordered vancomycin with directions 
to infuse over 6 hours 
 Override reason: “Patient has taken 
previously without allergic 
reaction/patient has tolerated 
previously” 
 Development of red man 
syndrome/patchy macular rash 
despite infusion over 6 hours 
 Inappropriate override 
 Definite ADE 
 Occurrence of ADE: ICU 
 Severity: significant  
 Preventable 
Geriatric  Clonazepam 
 1 mg twice daily 
 Desaturation on floor, requiring 
readmission to ICU 
 Inappropriate override 
 Definite ADE 
 Occurrence of ADE: 
Floor 
 Severity: life-threatening 
 Preventable 
Geriatric  Clonazepam 
 1 mg three times daily 
 Home medication 
 Increased lethargy; clonazepam 
changed to as needed dose 
 Inappropriate override 
 Definite ADE 
 Occurrence of ADE: ICU 
 Severity: serious 
 Preventable 
Geriatric  Fluphenazine 
 5 mg three times daily 
 Somnolence attributed to medication 
 Inappropriate override 
 Definite ADE 
 Occurrence of ADE: ICU 
 Severity: serious 
 Preventable 
Renal  Glyburide 
 5 mg daily 
 Home medication 
 Development of acute kidney injury; 
blood glucose readings of 61 and 49, 
requiring administration of dextrose 
and juice  
 Inappropriate override 
 Definite ADE 
 Occurrence of ADE: ICU 
 Severity: serious 
 Preventable 
Renal  Hydrochlorothiazide  
 Home medication 
 Elevation of serum creatinine by 0.6 
within 48 hours and decreased urine 
output; potential other causes of 
elevation 
 Inappropriate override 
 Probable ADE 
 Occurrence of ADE: ICU 
 Severity: significant 
 Preventable 
ADE = adverse drug event; ICU = intensive care unit 
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Figure Legends 
 
 
 
Figure 1. Screening and Inclusion  
 
 
 
 
 
